Silence Therapeutics plc (NASDAQ:SLN) Shares Sold by Millennium Management LLC

Millennium Management LLC reduced its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 57.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 473,552 shares of the company's stock after selling 636,678 shares during the period. Millennium Management LLC owned about 1.58% of Silence Therapeutics worth $3,258,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of SLN. Barclays PLC boosted its holdings in Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after acquiring an additional 2,793 shares in the last quarter. Bank of America Corp DE raised its position in Silence Therapeutics by 48,165.6% in the 4th quarter. Bank of America Corp DE now owns 499,066 shares of the company's stock worth $3,434,000 after buying an additional 498,032 shares during the last quarter. Marshall Wace LLP raised its position in Silence Therapeutics by 190.3% in the 4th quarter. Marshall Wace LLP now owns 488,889 shares of the company's stock worth $3,364,000 after buying an additional 320,472 shares during the last quarter. Nantahala Capital Management LLC increased its position in shares of Silence Therapeutics by 424.8% during the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company's stock valued at $7,222,000 after purchasing an additional 849,676 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Silence Therapeutics during the 4th quarter valued at about $26,000. 98.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on SLN shares. Chardan Capital cut their price objective on Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a research note on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, March 7th. BMO Capital Markets decreased their price target on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Morgan Stanley decreased their price target on Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Finally, The Goldman Sachs Group reduced their target price on Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat, Silence Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $33.83.

Silence Therapeutics Stock Down 3.0%

Shares of SLN stock traded down $0.17 during trading hours on Tuesday, hitting $5.56. 72,233 shares of the company's stock were exchanged, compared to its average volume of 302,208. Silence Therapeutics plc has a fifty-two week low of $1.97 and a fifty-two week high of $22.47. The firm has a market cap of $166.41 million, a P/E ratio of -3.54 and a beta of 1.20. The firm has a 50 day moving average of $3.67 and a two-hundred day moving average of $5.07.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The company had revenue of $0.14 million during the quarter, compared to analysts' expectations of $3.58 million. Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. On average, equities analysts forecast that Silence Therapeutics plc will post -1.77 earnings per share for the current fiscal year.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.